Hopstem

company

About

Hopstem is a pharmaceutical company engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.

  • 1 - 10

Details

Last Funding Type
Series A
Industries
Biotechnology,Health Care
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$40M
Hopstem has raised a total of $40M in funding over 2 rounds. Their latest funding was raised on Oct 31, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 31, 2021 Series B $40M 1 Detail
May 27, 2021 Series A 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Hopstem is funded by 2 investors. Lilly Asia Ventures and Longmen Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Series B
Longmen Capital Series A